Stock DYN DYNE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Dyne Therapeutics, Inc.

Equities

DYN

US26818M1080

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 03/05/2024 am IST 		5-day change 1st Jan Change
26 USD +0.66% Intraday chart for Dyne Therapeutics, Inc. +9.73% +95.49%
30/04 Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target MT
25/03 Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell MT

Business Summary

Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.

Number of employees: 141

Managers

Managers TitleAgeSince
Jason Rhodes FOU
 Founder 54 01/17/01
Rick Scalzo DFI
 Director of Finance/CFO 38 01/19/01
John Najim CTO
 Chief Tech/Sci/R&D Officer 48 01/19/01
Oxana Beskrovnaya CTO
 Chief Tech/Sci/R&D Officer 63 27/20/27
Catherine Stehman-Breen CTO
 Chief Tech/Sci/R&D Officer 61 28/19/28
Wildon Farwell CTO
 Chief Tech/Sci/R&D Officer 49 04/21/04
Ashish Dugar CTO
 Chief Tech/Sci/R&D Officer - 08/21/08
Susanna High COO
 Chief Operating Officer 56 01/20/01
Amy Reilly IRC
 Investor Relations Contact 51 01/20/01
Daniel Wilson LAW
 General Counsel 53 01/20/01

Members of the board

Members of the board TitleAgeSince
Edward Hurwitz BRD
 Director/Board Member 60 01/18/01
David Lubner BRD
 Director/Board Member 60 01/20/01
Dirk Kersten BRD
 Director/Board Member 49 01/18/01
Jason Rhodes FOU
 Founder 54 01/17/01
Carlo Incerti BRD
 Director/Board Member 65 02/22/02
Catherine Stehman-Breen CTO
 Chief Tech/Sci/R&D Officer 61 28/19/28

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 86,177,719 85,700,570 ( 99.45 %) 0 99.45 %

Shareholders

NameEquities%Valuation
Atlas Venture Life Science Advisors LLC
9.811 %
7,957,636 9.811 % 226 M $
Forbion Capital Partners Management Holding BV
9.673 %
7,845,364 9.673 % 223 M $
RA Capital Management LP
6.428 %
5,213,661 6.428 % 148 M $
MPM BioImpact, Inc
6.105 %
4,951,303 6.105 % 141 M $
Deep Track Capital LP
5.548 %
4,500,000 5.548 % 128 M $
BlackRock Advisors LLC
4.468 %
3,624,132 4.468 % 103 M $
Citadel Advisors LLC (13f Subfiler)
3.765 %
3,053,440 3.765 % 87 M $
STATE STREET CORPORATION
2.882 %
2,337,141 2.882 % 66 M $
Vanguard Fiduciary Trust Co.
2.872 %
2,329,641 2.872 % 66 M $
Venrock Associates
2.680 %
2,173,913 2.680 % 62 M $

Company contact information

Dyne Therapeutics, Inc.

1560 Trapelo Road

02451, Waltham

+

http://www.dyne-tx.com
address Dyne Therapeutics, Inc.(DYN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
25.83 USD
Average target price
37.8 USD
Spread / Average Target
+46.34%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
DYNE THERAPEUTICS, INC. Stock Dyne Therapeutics, Inc.
+95.49% 2.23B
MODERNA, INC. Stock Moderna, Inc.
+26.28% 42.68B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.99% 42.4B
LONZA GROUP AG Stock Lonza Group AG
+45.32% 40.04B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.36% 24.94B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.47% 18.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.58% 12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.75% 11.95B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-2.02% 11.55B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. DYN Stock
  4. Company Dyne Therapeutics, Inc.